• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

    1/28/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

    Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.

    About 10x Genomics

    10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables, and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience, and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter). 

    Disclosure Information

    10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

    Contacts

    Investors: [email protected]

    Media: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-12-2025-302362387.html

    SOURCE 10x Genomics, Inc.

    Get the next $TXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    6/3/2024$24.00Hold
    Jefferies
    More analyst ratings

    $TXG
    SEC Filings

    See more
    • 10x Genomics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      6/5/25 4:09:39 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 144 filed by 10x Genomics Inc.

      144 - 10x Genomics, Inc. (0001770787) (Subject)

      5/22/25 4:44:06 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 144 filed by 10x Genomics Inc.

      144 - 10x Genomics, Inc. (0001770787) (Subject)

      5/22/25 4:36:27 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

      PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies. As part of the settlement, 10x expects that Bruker will pay $68 million in equal quarterly installments between the third quarter of 2025 and the second quarter of 2026, as well as ongoing royalties on sales of its spatial biology products through the life of the licensed patents. 

      5/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

      PLEASANTON, Calif., April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event. About 10x Genomics

      4/30/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials